^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Pexa-Vec (pexastimogene devacirepvec)

    i
    Associations
    News

    Trials

    Company:
    GC Biopharma, Lee's Pharm, SillaJen, Transgene
    Drug class:
    GM-CSF agonist, Vascular disrupting agent, EGFR modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer (NCT03206073)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/24/2023
    Initiation :
    12/07/2017
    Primary completion :
    09/24/2020
    Completion :
    06/30/2022
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Imjudo (tremelimumab-actl) • Pexa-Vec (pexastimogene devacirepvec)
    A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (NCT02630368)
    Phase 1/2
    Institut Bergonié
    Recruiting
    Last update posted :
    02/02/2022
    Initiation :
    09/18/2015
    Primary completion :
    05/01/2023
    Completion :
    11/01/2024
    HER-2
    |
    HER-2 negative
    |
    Bavencio (avelumab) • cyclophosphamide • Pexa-Vec (pexastimogene devacirepvec) • cyclophosphamide intravenous
    Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (NCT01394939)
    Phase 1/2
    Jennerex Biotherapeutics
    Completed
    Last update posted :
    01/08/2021
    Initiation :
    01/01/2012
    Primary completion :
    06/01/2015
    Completion :
    10/01/2015
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    irinotecan • Pexa-Vec (pexastimogene devacirepvec)
    Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS) (NCT02562755)
    Phase 3
    SillaJen, Inc.
    Completed
    Last update posted :
    12/16/2020
    Initiation :
    10/01/2015
    Primary completion :
    07/01/2020
    Completion :
    07/01/2020
    CD8 • CD4
    |
    sorafenib • Pexa-Vec (pexastimogene devacirepvec)
    Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (NCT01169584)
    Phase 1
    Jennerex Biotherapeutics
    Completed
    Last update posted :
    01/21/2016
    Initiation :
    08/01/2010
    Primary completion :
    03/01/2012
    Completion :
    11/01/2014
    CD4
    |
    Pexa-Vec (pexastimogene devacirepvec)
    Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (NCT01380600)
    Phase 1b
    Jennerex Biotherapeutics
    Completed
    Last update posted :
    01/08/2016
    Initiation :
    07/01/2010
    Primary completion :
    11/01/2012
    Completion :
    12/01/2015
    RAS
    |
    RAS mutation
    |
    Pexa-Vec (pexastimogene devacirepvec)
    Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (NCT00625456)
    Phase 1
    Jennerex Biotherapeutics
    Completed
    Last update posted :
    12/03/2015
    Initiation :
    06/01/2008
    Primary completion :
    04/01/2010
    Completion :
    06/01/2014
    CD4
    |
    Pexa-Vec (pexastimogene devacirepvec)